These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 20231677)

  • 21. Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer.
    Wolpin BM; Ng K; Zhu AX; Abrams T; Enzinger PC; McCleary NJ; Schrag D; Kwak EL; Allen JN; Bhargava P; Chan JA; Goessling W; Blaszkowsky LS; Supko JG; Elliot M; Sato K; Regan E; Meyerhardt JA; Fuchs CS
    Oncologist; 2013; 18(4):377-8. PubMed ID: 23580238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial.
    Ito T; Okusaka T; Ikeda M; Igarashi H; Morizane C; Nakachi K; Tajima T; Kasuga A; Fujita Y; Furuse J
    Jpn J Clin Oncol; 2012 Oct; 42(10):903-11. PubMed ID: 22859827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
    Ferolla P; Brizzi MP; Meyer T; Mansoor W; Mazieres J; Do Cao C; Léna H; Berruti A; Damiano V; Buikhuisen W; Grønbæk H; Lombard-Bohas C; Grohé C; Minotti V; Tiseo M; De Castro J; Reed N; Gislimberti G; Singh N; Stankovic M; Öberg K; Baudin E
    Lancet Oncol; 2017 Dec; 18(12):1652-1664. PubMed ID: 29074099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001).
    White DA; Schwartz LH; Dimitrijevic S; Scala LD; Hayes W; Gross SH
    J Thorac Oncol; 2009 Nov; 4(11):1357-63. PubMed ID: 19745764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis.
    Escudier B; Molinie V; Bracarda S; Maroto P; Szczylik C; Nathan P; Negrier S; Weiss C; Porta C; Grünwald V; Albiges L
    Eur J Cancer; 2016 Dec; 69():226-235. PubMed ID: 27680407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients.
    Yao J; Wang JY; Liu Y; Wang B; Li YX; Zhang R; Wang LS; Liu L
    Med Oncol; 2014 Dec; 31(12):251. PubMed ID: 25395378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
    Yoo C; Lee J; Rha SY; Park KH; Kim TM; Kim YJ; Lee HJ; Lee KH; Ahn JH
    Invest New Drugs; 2013 Dec; 31(6):1602-8. PubMed ID: 24037083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic implications of mTOR inhibitors in the treatment of gastric cancer.
    Bu Z; Ji J
    Curr Cancer Drug Targets; 2013 Feb; 13(2):121-5. PubMed ID: 23215721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
    Pavel ME; Hainsworth JD; Baudin E; Peeters M; Hörsch D; Winkler RE; Klimovsky J; Lebwohl D; Jehl V; Wolin EM; Öberg K; Van Cutsem E; Yao JC;
    Lancet; 2011 Dec; 378(9808):2005-2012. PubMed ID: 22119496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experience with everolimus therapy for patients with metastatic renal cancer in Hungary].
    Maráz A; Bodoky G; Dank M; Géczi L; Kahán Z; Mangel L; Révész J; Szűcs M
    Magy Onkol; 2014 Mar; 58(1):4-9. PubMed ID: 24712001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).
    Lorenzen S; Knorrenschild JR; Pauligk C; Hegewisch-Becker S; Seraphin J; Thuss-Patience P; Kopp HG; Dechow T; Vogel A; Luley KB; Pink D; Stahl M; Kullmann F; Hebart H; Siveke J; Egger M; Homann N; Probst S; Goetze TO; Al-Batran SE
    Int J Cancer; 2020 Nov; 147(9):2493-2502. PubMed ID: 32339253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Everolimus in Patients With Advanced Follicular-Derived Thyroid Cancer: Results of a Phase II Clinical Trial.
    Schneider TC; de Wit D; Links TP; van Erp NP; van der Hoeven JJ; Gelderblom H; Roozen IC; Bos M; Corver WE; van Wezel T; Smit JW; Morreau H; Guchelaar HJ; Kapiteijn E
    J Clin Endocrinol Metab; 2017 Feb; 102(2):698-707. PubMed ID: 27870581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Everolimus Plus Letrozole for Treatment of Patients With HR
    Safra T; Kaufman B; Kadouri L; Efrat Ben-Baruch N; Ryvo L; Nisenbaum B; Evron E; Yerushalmi R
    Clin Breast Cancer; 2018 Apr; 18(2):e197-e203. PubMed ID: 29097108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer.
    Shen YC; Li CP; Yen CJ; Hsu C; Lin YL; Lin ZZ; Chen LT; Su WC; Chao Y; Yeh KH; Cheng AL
    Oncology; 2014; 87(2):104-13. PubMed ID: 25011938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
    Schöffski P; Reichardt P; Blay JY; Dumez H; Morgan JA; Ray-Coquard I; Hollaender N; Jappe A; Demetri GD
    Ann Oncol; 2010 Oct; 21(10):1990-1998. PubMed ID: 20507881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201).
    Bando H; Doi T; Muro K; Yasui H; Nishina T; Yamaguchi K; Takahashi S; Nomura S; Kuno H; Shitara K; Sato A; Ohtsu A
    Eur J Cancer; 2016 Jul; 62():46-53. PubMed ID: 27208903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma.
    Kim DW; Oh DY; Shin SH; Kang JH; Cho BC; Chung JS; Kim H; Park KU; Kwon JH; Han JY; Kim MJ; Bang YJ
    BMC Cancer; 2014 Nov; 14():795. PubMed ID: 25362970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers.
    Seront E; Rottey S; Sautois B; Kerger J; D'Hondt LA; Verschaeve V; Canon JL; Dopchie C; Vandenbulcke JM; Whenham N; Goeminne JC; Clausse M; Verhoeven D; Glorieux P; Branders S; Dupont P; Schoonjans J; Feron O; Machiels JP
    Ann Oncol; 2012 Oct; 23(10):2663-2670. PubMed ID: 22473592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
    Zhu AX; Kudo M; Assenat E; Cattan S; Kang YK; Lim HY; Poon RT; Blanc JF; Vogel A; Chen CL; Dorval E; Peck-Radosavljevic M; Santoro A; Daniele B; Furuse J; Jappe A; Perraud K; Anak O; Sellami DB; Chen LT
    JAMA; 2014 Jul; 312(1):57-67. PubMed ID: 25058218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.